A Biotech Bash - Recs and Wrecks Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : A Biotech Bash - Recs and Wrecks

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: r. peter Dale who wrote (17)	8/25/1997 10:20:00 PM
From: Henry Niman	of 171

Peter, Molecules in polypeptide hormone signal transduction pathway (such as SRC) as well as the extracellular recptors have SH2/SH3 domains which is where most of ARIA's focus is. As far as consultants are concerned, Ron Evans is LGND's exclusive consultant. They patent just about everything he does regarding intracellular receptors (over 150 issued and more than that pending in the US alone). Ron Evans (as well as David Levy and Jim Darnell) have huge amounts of LGND stock and they are much more involved than the average casual consultant. Ron Evans was the scientific founder of LGND and heads their scientific advisory board.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next